Dihydropyridine calcium channel blockers: Basic pharmacological similarities but fundamental therapeutic differences

Journal of Hypertension

Volumn 22, Issue 9, 2004, Pages 1641-1648

  Meredith, Peter A ^a   Elliott, Henry L ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Calcium channel blocker; Cardiovascular outcome; Dihydropyridine; Long duration of action; Sympathetic activation

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; LACIDIPINE; LERCANIDIPINE; MANIDIPINE; NIFEDICRON; NIFEDIPINE; NISOLDIPINE; UNCLASSIFIED DRUG; VERAPAMIL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG MECHANISM; HEART RATE; HUMAN; HYPERTENSION; LONG TERM CARE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 4344566603     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200409000-00002     Document Type: Review

References (43)

1. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-372.
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288:2981-2997.
3. Repine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist versus a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST), a randomised controlled trial. JAMA 2003; 290:2805-2816.
4. Staessen JA. Fagard R. Thijs L. Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350:757-764.
5. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study. Lancet 1999; 354:1751-1756.
6. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356:359-365.
7. Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 1998; 16:1823-1829.
8. Gong L, Zhang W, Zhu V, Zhu J, Kong D, Page V, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14:1237-1245.
9. Appel LJ. The verdict fom ALLHAT - thiazide diuretics are the preferred initial therapy for hypertension. JAMA 2002; 288:3039-3042.
10. Herbette LG, Gaviraghi G, Tulenko T, Mason RP. Molecular interaction between lacidipine and biological membranes. J Hypertens Suppl 1993; 11:313-19.
11. Bainbridge AD, Herlihy O, Meredith PA, Elliott HL. A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices. Eur J Clin Pharmacol 1993; 45:425-430.
12. Donnelly R, Elliott HL, Meredith PA. Concentration - effect analysis of antihypertensive drug response - focus on calcium antagonists. Clin Pharmacokinet 1994; 26:472-485.
13. Meredith PA, Donnelly R, Elliott HL. Prediction and optimisation of the antihypertensive response to nifedipine. Blood Press 1994; 3:303-308.
14. Abernethy DR, Gutkowska J, Winterbottom LM. Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: Pharmacodynamics in relation to disposition. Clin Pharmacol Ther 1990; 48:76-86.
15. Donnelly R, Meredith PA, Miller SHK, Howie CA, Elliott HL. Pharmacodynamic modelling of the antihypertensive response to amlodipine. Clin Pharmacol Ther 1993; 54:303-310.
16. Edgar B, Regardh CG, Lundborg P, Romare S, Nyberg G, Ronn O. Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses. Biopharm Drug Dispos 1987; 8:235-248.
17. Blychert E, Edgar B, Elmfeldt D, Hedner T. Plasma concentration-effect relationships for felodipine: a meta analysis. Clin Pharmacol Ther 1992; 52:80-89.
18. Meredith PA. Pharmacokinetics and pharmacodynamics in evaluating the duration of action of antihypertensive drugs. JAMA South East Asia 1994; 10:20-25.
19. Kleinbloesem CH, van Brummelen P, van de Linde JA, Voogd PJ, Breimer DD. Nifedipine; kinetics and dynamics in healthy subjects. Clin Pharm Ther 1984; 35:742-749.
20. Murphy MB, Scriven AM, Brown MJ, Causon R. Dollery CT. The effects of nifedipine and hydralazine induced hypotension on sympathetic activity. Eur J Clin Pharmacol 1982; 23:479-482.
21. Lederballe-Pederson O, Christensen NJ, Raemsch KD. Comparison of acute effects of nifedipine in normotensive and hypertensive man. J Cardiovasc Pharmacol 1980; 2:357-366.
22. Kiowski W, Bertel O, Erne P, Bolli P, Hulthen UL, Ritz R, et al. Haemodynamic and reflex responses to acute and chronic antihypertensive therapy with the calcium entry blocker nifedipine. Hypertension 1983; 5(suppl 1):70-74.
23. Bruun NE, Ibsen H, Nielsen F, Nielsen MD. Moelbak AG. Hartling OJ. Lack of effect of nifedipine on counter-regulatory mechanisms in essential hypertension. Hypertension 1986; 8:655-661.
24. Muiesan G, Agabiti-Rosei E, Castellano M, Alicandri CL, Corea L, Fariello R, et al. Antihypertensive and humoral effects of verapamil and nifedipine in essential hypertension. J Cardiovasc Pharmacol 1982; 4(suppl 3):S325-329.
25. Katzman PL, Hulthen UL, Hokfelt B. The effect of 8 weeks treatment with the calcium antagonist felodipine on blood pressure, heart rate, working capacity, plasma renin activity, plasma angiotensin II, urinary catecholamines and aldosterone in patients with essential hypertension. Br J Clin Pharmacol 1986; 21:633-640.
26. Donnelly R, Elliott HL, Meredith PA, Reid JL. Nifedipine in essential hypertension: responses and concentration - effect relationships in individual patients. Hypertension 1988; 12:443-449.
27. Leenen FHH, Holliwell DL. Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. Am J Cardiol 1992; 69:639-645.
28. De Champlain J, Karas M, Nguyen P, Cartier P, Wistaff R, Toal CB, et al. Different effects of nifedipine and amlodipine on circulating catecholamines levels in essential hypertensive patients. J Hypertens 1998; 16:1357-1369.
29. Grossman E, Messerli FH. Effect of calcium antagonists on plasma norepinephrine levels, heart rate and blood pressure. Am J Cardiol 1997; 80:1453-1458.
30. Phillips RA, Ardeijan M, Shimabukuro S, Goldman ME, Garbowit DL, Eison HB, et al. Normalisation of left ventricular mass and associated changes in neurohormones and atrial natriuretic peptide after 1 year of sustained nifedipine therapy for severe hypertension. J Am Coll Cardiol 1991; 17:1595-1602.
31. Leenen FH, Fourney A. Comparison of the effects of amlodipine and diltiazem on 24-hour blood pressure, plasma catecholamines, and left ventricular mass. Am J Cardiol 1996; 78:203-207.
32. Fogari R, Mugellini A, Zoppi A, Corradi L, Rinaldi A. Derosa G, et al. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens 2003; 16:596-599.
33. Fogari R, Zoppi A, Corradi L, Preti P, Malamani GD, Mugellini A, et al. Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. J Hypertens 2000; 18: 1871-1875.
34. Julius S. Sympathetic hyperactivity and coronary risk in hypertension. Hypertension 1993; 21:886-893.
35. Cruikshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992; 6:85-903.
36. Schlaich MP, Schmieder RE. Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertensive agents. Am J Hypertens 1998; 11:1394-1404.
37. Leenen FHH, Myers MG, Joyner CD, Toal CB. Differential effects of once daily antihypertensive drugs on blood pressure, left ventricular mass and sympathetic activity: nifedipine GITS versus felodipine ER versus enalapril. Can J Cardiol 2002; 18:1285-1293.
38. Anonymous. Dihydropyridines are not substitutable without careful monitoring. S Afr Med J 2002; 92:596.
39. Rayner B, Buchanan-Lee B, Brink J, Opie L. Generic substitution - is it safe in patients at high cardiovascular risk? S Afr Med J 2002; 92: 603-604.
40. British Medical Association and Royal Pharmaceutical Society of Great Britain. Calcium channel blockers - nifedipine modified release. In: British National Formulary, Vol. 46. Oxford: Pharmaceutical Press; 2003, section 2.6.2 (Available at website: www.bnf.org).
41. Schug BS, Brendel E, Wonnemann M, Wolf D, Wargenau M, Dingler A, Blume HH. Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast. Eur J Clin Pharmacol 2002; 58:119-125.
42. Schug BS, Brendel E, Chantraine E, Wolf D, Martin W, Schall R, Blume HH. The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast. Br J Clin Pharmacol 2002; 53:582-588.
43. Schug BS, Brendel E, Wolf D, Wonnemann M, Wargenau M, Blume HH. Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union. Eur J Pharm Sci 2002; 15:279-285.